FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060291323> ?p ?o ?g. }

• W2060291323 abstract "Patients with neuromuscular diseases ask relatively simple questions. They want a timely diagnosis, and information about prognosis and effects of disease on their personal functional status. With respect to treatment, patients long for a cure but most understand that they will have to reconcile to rehabilitation or even palliative treatment.With respect to diagnosis, neurologists are trained to detect impairments, neurological signs and symptoms such as motor weakness using the MRC scale, or a Babinski sign. Also, though usually not in a structured way neurologists try to evaluate disability, such as not being able to go up the stairs or cycling. Functional status may be measured with the sickness impact profile (SIP) or the modified Rankin scale. Finally effects of disease on participation, for example not being able to work or taking part in sports, and on perceived health will be estimated. Measures of disability, participation and perceived health are increasingly being used as outcome measures in clinical trials [1].Fatigue may be another underestimated symptom of neuromuscular disease [2]. That can be explained by ignorance as most patients with the exception of patients with myasthenia gravis or myotonic dystrophy do not spontaneously complain of fatigue. Many severely handicapped neuromuscular patients keep trying to participate in social life and work. In contrast, patients with the chronic fatigue syndrome have no or little objective signs and maximal decrease of participation and perceived health [2]. Yet, if fatigue would be a common additional feature of neuromuscular diseases, neurologists must be aware in order to better comprehend their patients and to develop new treatment strategies.This issue of the Journal of Neurology contains two papers on fatigue in hereditary neuromuscular diseases. Dr. Hagemans did a cross-sectional study using a questionnaire with the Fatigue Severity Scale in 225 patients with late-onset Pompe disease [3]. About 67% had severe fatigue. Possible confounding factors were wheelchair dependency and respiratory support in about half of the patients, but 59% of patients without these aids also had severe fatigue. Previously this group investigated quality of life in lateonset Pompe patients using the SF-36 [4]. Interestingly, they found that these patients score only slightly lower than the general population on the mental health domains, making depression or decreased vitality as explanations for fatigue unlikely [3, 4]. The second paper shows that fatigue and pain can be relevant symptoms in facioscapulohumeral muscular dystrophy (FSHD) [5]. Both groups suggest that fatigue is probably underreported in these slowly progressive neuromuscular diseases.Some caution with the role of confounding factors seems justified. The question whether patients with late onset Pompe disease and no respiratory aid have respiratory insufficiency that explains fatigue, can only be answered by actually measuring pulmonary function. In FSHD impaired shoulder function that is difficult to quantify, will affect quality of life and could explain fatigue.Nevertheless, the notion that fatigue may be part of the phenotype of neuromuscular disease is important. To my opinion, the wear and tear from having to live a life long with the consequences of a neuromuscular disease may be one explanation for fatigue. Severe fatigue will affect participation and perceived health. Neurologists must learn to measure fatigue during history taking. Neurologists can also develop interventions. For instance, it has recently been demonstrated that simple bicycle exercise training may help to decrease fatigue in patients following Guillain-Barre syndrome [6]." @default.
• W2060291323 created "2016-06-24" @default.
• W2060291323 creator A5064268727 @default.
• W2060291323 date "2007-02-26" @default.
• W2060291323 modified "2023-09-26" @default.
• W2060291323 title "Fatigue is part of the burden of neuromuscular diseases" @default.
• W2060291323 cites W1996344495 @default.
• W2060291323 cites W1998256512 @default.
• W2060291323 cites W2027671694 @default.
• W2060291323 cites W2091960601 @default.
• W2060291323 cites W2118159460 @default.
• W2060291323 cites W2160660606 @default.
• W2060291323 cites W2338837901 @default.
• W2060291323 doi "https://doi.org/10.1007/s00415-006-0436-0" @default.
• W2060291323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2779378" @default.
• W2060291323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17325819" @default.
• W2060291323 hasPublicationYear "2007" @default.
• W2060291323 type Work @default.
• W2060291323 sameAs 2060291323 @default.
• W2060291323 citedByCount "10" @default.
• W2060291323 countsByYear W20602913232012 @default.
• W2060291323 countsByYear W20602913232013 @default.
• W2060291323 countsByYear W20602913232014 @default.
• W2060291323 countsByYear W20602913232017 @default.
• W2060291323 countsByYear W20602913232019 @default.
• W2060291323 countsByYear W20602913232020 @default.
• W2060291323 crossrefType "journal-article" @default.
• W2060291323 hasAuthorship W2060291323A5064268727 @default.
• W2060291323 hasBestOaLocation W20602913231 @default.
• W2060291323 hasConcept C118552586 @default.
• W2060291323 hasConcept C126322002 @default.
• W2060291323 hasConcept C16568411 @default.
• W2060291323 hasConcept C1862650 @default.
• W2060291323 hasConcept C2776356578 @default.
• W2060291323 hasConcept C2779134260 @default.
• W2060291323 hasConcept C2779889316 @default.
• W2060291323 hasConcept C71924100 @default.
• W2060291323 hasConcept C99508421 @default.
• W2060291323 hasConceptScore W2060291323C118552586 @default.
• W2060291323 hasConceptScore W2060291323C126322002 @default.
• W2060291323 hasConceptScore W2060291323C16568411 @default.
• W2060291323 hasConceptScore W2060291323C1862650 @default.
• W2060291323 hasConceptScore W2060291323C2776356578 @default.
• W2060291323 hasConceptScore W2060291323C2779134260 @default.
• W2060291323 hasConceptScore W2060291323C2779889316 @default.
• W2060291323 hasConceptScore W2060291323C71924100 @default.
• W2060291323 hasConceptScore W2060291323C99508421 @default.
• W2060291323 hasIssue "7" @default.
• W2060291323 hasLocation W20602913231 @default.
• W2060291323 hasLocation W20602913232 @default.
• W2060291323 hasLocation W20602913233 @default.
• W2060291323 hasLocation W20602913234 @default.
• W2060291323 hasOpenAccess W2060291323 @default.
• W2060291323 hasPrimaryLocation W20602913231 @default.
• W2060291323 hasRelatedWork W1975963112 @default.
• W2060291323 hasRelatedWork W2060291323 @default.
• W2060291323 hasRelatedWork W2066080511 @default.
• W2060291323 hasRelatedWork W2120185406 @default.
• W2060291323 hasRelatedWork W2144003136 @default.
• W2060291323 hasRelatedWork W2998570841 @default.
• W2060291323 hasRelatedWork W2999167632 @default.
• W2060291323 hasRelatedWork W317867808 @default.
• W2060291323 hasRelatedWork W4206357446 @default.
• W2060291323 hasRelatedWork W4236903608 @default.
• W2060291323 hasVolume "254" @default.
• W2060291323 isParatext "false" @default.
• W2060291323 isRetracted "false" @default.
• W2060291323 magId "2060291323" @default.
• W2060291323 workType "article" @default.